Status:
UNKNOWN
Drug Monitoring in Critically Ill Patients During Extracorporeal Life Support
Lead Sponsor:
Goethe University
Conditions:
Drug Monitoring of Antiinfectives in Critically Ill Patients Receiving Extracorporeal Life Support
Eligibility:
All Genders
18-99 years
Brief Summary
About 70% of critically ill patients require antiinfective therapy. Optimal antibiotic dosing is key to improve patient survival, reduce toxic effects and minimise the emergence of bacterial resistanc...
Detailed Description
About 70% of critically ill patients require antiinfective therapy. Optimal antibiotic dosing is key to improve patient survival, reduce toxic effects and minimise the emergence of bacterial resistanc...
Eligibility Criteria
Inclusion
- Age \> 18
- Informed consent
- Clinical infection indicated for intravenous therapy with at least one of the following index anti-infectives: meropenem, teicoplanin, linezolid, piperacillin/tazobactam, levofloxacin and/oraciclovir
- Application of an ECLS procedure with an expected duration of at least five days
Exclusion
- Pregnancy
- Massive Hemorrhage
Key Trial Info
Start Date :
January 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04127305
Start Date
January 1 2019
End Date
May 31 2022
Last Update
February 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universital Hospital Frankfurt / Main
Frankfurt am Main, Deutschland, Germany, 60529